QuatRx Pharmaceuticals is focused on discovering, licensing, developing and commercializing compounds in the endocrine, metabolic and cardiovascular therapeutic areas.
Investors 1
Funding Rounds 1
| Date | Series | Amount | Investors |
| 23.05.2007 | IPO | $44M | - |
Mentions in press and media 2
| Date | Title | Description |
| 13.09.2016 | Millendo Launches Phase 2b Study of PCOS Drug After Year of Growth | Share Share on Facebook Share on Twitter LinkedIn Email Reprints
Millendo Therapeutics, the Ann Arbor, MI-based biotech company developing drugs to treat endocrine diseases, last month began Phase 2b clinical trials for MLE4901, a non-hormo... |
| 23.05.2007 | QuatRx Pharma draws $44M after pulling IPO | Ann Arbor, Mich., specialty pharmaceutical company QuatRx Pharmaceuticals raised $44 million in a fifth funding round following the withdrawal of its initial offering last July. Like the much better-known Jazz Pharmaceuticals, QuatRx acquir... |
Reviews 0
